Retatrutide, developed by Soma Pharmaceuticals , is receiving increasing attention as a novel method for obesity control . This innovative compound merges the properties of a GLP-1 receptor activator and a GIP receptor agonist , more info designed to not only promote reduced body fat but also address associated metabolic issues . Initial human tria